Sex: M
Vaccine: COVID19
Symptoms: Hair follicle tumour benign, Microscopy, Pathology test, Physical examination
Clinical narrative: slowly growing shoulder mass, diagnosed as pilomatrixoma; The initial case was missing the following minimum criteria: Reporter with no First-Hand knowledge. Upon receipt of follow-up info on 18Dec2023, this case now contains all required info to be considered valid.   This is a literature report.   A 65-year-old male patient received BNT162b2 (BNT162B2), in 2021 as dose 1, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing); "High cholesterol" (unspecified if ongoing); "Obstructive sleep apnea" (unspecified if ongoing); "Psoriasis" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: HAIR FOLLICLE TUMOUR BENIGN (medically significant), 3 months after the suspect product(s) administration, outcome "recovered", described as "slowly growing shoulder mass, diagnosed as pilomatrixoma". The patient underwent the following laboratory tests and procedures: Microscopy: disrupted fragments of soft tissue with, notes: solid nests of basaloid cells undergoing abrupt trichilemmal-type keratinization and multinucleated giant cell reaction, consistent with the diagnosis of Pilomatrixoma (Non-cancerous pilomatrixoma); Pathology test: Pilomatrixoma; Physical examination: A freely mobile 3 cm mass/cyst, notes: in the left upper lateral shoulder with no sign of infection or abscess. Therapeutic measures were taken as a result of hair follicle tumour benign.  Clinical information: The patient presented with left lateral shoulder mass that has been slowly growing for about 1.5 years. The patient reported that the mass appeared at the exact vaccination site 3 months after receiving first dose of Pfizer BioNTech covid 19 mRNA vaccine. A freely mobile 3 cm mass/cyst in the left upper lateral shoulder with no sign of infection or abscess. The impression was left upper extremity mass/lump, and possible diagnosis included an epidermal inclusion cyst, granuloma, or lipoma. The patient expressed interest in the surgical intervention, and an excision under local anaesthetic was performed. Intraoperatively a 3 cm cystic lesion containing sebum like material without a capsule was identified and excised. There was no sign of reoccurrence at the tree months post operative check-up.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of serious events HAIR FOLLICLE TUMOUR cannot be totally excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : GB-PFIZER INC-PV202300201085 Same reporter/ Different patients;GB-PFIZER INC-PV202300201086 Same reporter/ Different patients;